Sort by
Previous Page Page 1 of 8 Next Page
  1. Research

    Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

    Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluat...

    Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf and Matthias Klinger

    Experimental Hematology & Oncology 2017 6:14

    Published on: 18 May 2017

  2. Case report

    Cyclosporine is a potential curative treatment option for advanced thymoma

    Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the fir...

    Yusuke Isshiki, Hiroaki Tanaka, Yoshio Suzuki and Yukihiro Yoshida

    Experimental Hematology & Oncology 2017 6:13

    Published on: 3 May 2017

  3. Case report

    Metastatic squamous cell carcinoma of colon from esophageal cancer

    Esophageal cancer including squamous cell carcinoma (SCC) and adenocarcinoma represents 4% of all cancers in the United States. Patients with esophageal cancer frequently present with locally advanced disease,...

    Natasha Garg, Constance Stoehr, Yan Shi Zhao, Heather Rojas and Chung-Tsen Hsueh

    Experimental Hematology & Oncology 2017 6:11

    Published on: 18 April 2017

  4. Case report

    Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions

    Osteolytic bone lesions and hypercalcemia without peripheral blasts B-cell acute lymphoblastic leukemia (B-ALL) is reported in children but rarely seen in adults.

    Nikki Charlotta Paul Granacher, Zwi N. Berneman, Wilfried Schroyens, Ann L. R. Van de Velde, Anke Verlinden and Alain P. A. Gadisseur

    Experimental Hematology & Oncology 2017 6:9

    Published on: 11 April 2017

  5. Case report

    Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

    The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK...

    Riccardo Marconcini, Luca Galli, Andrea Antonuzzo, Simona Bursi, Claudia Roncella, Gabriella Fontanini, Elisa Sensi and Alfredo Falcone

    Experimental Hematology & Oncology 2017 6:6

    Published on: 21 March 2017

  6. Research

    A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises

    Chemotherapy-induced polyneuropathy (CIPN) is a common toxicity after chemotherapy, immunomodulatory drugs or proteasome inhibitors, which is difficult to treat and may also have impact on quality of life. The...

    Stefan S. Schönsteiner, Heidi Bauder Mißbach, Axel Benner, Silja Mack, Thomas Hamel, Michael Orth, Bernhard Landwehrmeyer, Sigurd D. Süßmuth, Carolin Geitner, Regine Mayer-Steinacker, Anneliese Riester, Andrea Prokein, Elfriede Erhardt, Jelena Kunecki, Anna M. Eisenschink, Rainer Rawer…

    Experimental Hematology & Oncology 2017 6:5

    Published on: 7 February 2017

  7. Case report

    Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab

    Atypical hemolytic uremic syndrome is a rare disorder which is known to cause acute thrombotic microangiopathy during pregnancy with poor maternal and fetal outcomes. Atypical hemolytic uremic syndrome is cau...

    Gabriela Andries, Michael Karass, Srikanth Yandrapalli, Katherine Linder, Delong Liu, John Nelson, Rahul Pawar and Savneek Chugh

    Experimental Hematology & Oncology 2017 6:4

    Published on: 13 January 2017

  8. Case report

    Molecular classification of tissue from a transformed non-Hogkin’s lymphoma case with unexpected long-time remission

    The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing an...

    Julie Støve Bødker, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Rasmus Froberg Brøndum, Maria Bach Laursen, Steffen Falgreen, Mette Nyegaard, Alexander Schmitz, Lasse Hjort Jakobsen, Anna Amanda Schönherz, Hanne Due, Linn Reinholdt, Martin Bøgsted, Karen Dybkær and Hans Erik Johnsen

    Experimental Hematology & Oncology 2017 6:3

    Published on: 11 January 2017

  9. Case report

    Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

    Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF onco...

    Michele Moschetta, Gabriel Mak, Joana Hauser, Catriona Davies, Mario Uccello and Hendrik-Tobias Arkenau

    Experimental Hematology & Oncology 2017 6:1

    Published on: 10 January 2017

  10. Short report

    Pim1 kinase regulates c-Kit gene translation

    Receptor tyrosine kinase, c-Kit (CD117) plays a pivotal role in the maintenance and expansion of hematopoietic stem/progenitor cells (HSPCs). Additionally, over-expression and/or mutational activation of c-Kit...

    Ningfei An, Bo Cen, Houjian Cai, Jin H. Song, Andrew Kraft and Yubin Kang

    Experimental Hematology & Oncology 2016 5:31

    Published on: 30 December 2016

  11. Review

    Long noncoding RNAs: pivotal regulators in acute myeloid leukemia

    Long noncoding RNAs (lncRNAs) have emerged as a class of pivotal regulators of gene expression. Recent studies have shown that lncRNAs contribute to the initiation, maintenance, and development of acute myeloi...

    Shuyong Wei and Kankan Wang

    Experimental Hematology & Oncology 2016 5:30

    Published on: 12 December 2016

  12. Review

    Paraneoplastic neurological complications of breast cancer

    Breast cancer is the most frequent cause of cancer of women in much of the world. In countries with screening programs, breast cancer is often detected before clinical symptoms are apparent, but occasionally t...

    Ibrahim Fanous and Patrick Dillon

    Experimental Hematology & Oncology 2016 5:29

    Published on: 24 October 2016

  13. Research

    Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden

    Pegylated-interferon alpha (PegINFα) treatment of patients with polycythemia vera (PV) and essential thrombocythemia (ET) has resulted in long-term clinical response, decreased JAK2 V61...

    Magdalena Kovacsovics-Bankowski, Todd W. Kelley, Olga Efimova, Soo Jin Kim, Andrew Wilson, Sabina Swierczek and Josef Prchal

    Experimental Hematology & Oncology 2016 5:28

    Published on: 27 September 2016

  14. Rapid communication

    Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia

    Acute myeloid leukemia (AML) carrying nucleophosmin 1 (NPM1) mutations (NPMc+) is regarded as a separate entity of myeloid neoplasms due to its distinct biological and clinical features. However, NPMc+ alone disp...

    Hanna Grauers Wiktorin, Tina Nilsson, Ann Jansson, Lars Palmqvist and Anna Martner

    Experimental Hematology & Oncology 2016 5:25

    Published on: 11 August 2016

  15. Review

    Novel melanoma therapy

    With the rapid succession of new effective agents for melanoma in the recent years, the paradigm for treatment of metastatic melanoma is changing. The success of combining multiple effective agents compared wi...

    Eddy C. Hsueh and Kalyan C. Gorantla

    Experimental Hematology & Oncology 2016 5:23

    Published on: 8 August 2016

  16. Research

    Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution

    Blocking mTOR (molecular target of rapamycin) by sirolimus has been shown to suppress cellular respiration. The bearing of this impaired cellular bioenergetics on the mode-of-action of mTOR inhibitors has yet ...

    Suleiman Al-Hammadi, Saeeda Almarzooqi, Alia Albawardi and Abdul-Kader Souid

    Experimental Hematology & Oncology 2016 5:22

    Published on: 29 July 2016

  17. Case report

    Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases

    B Acute Lymphoblastic leukemia (B-ALL) with Philadelphia chromosome (Ph′) is a neoplasm of lymphoblast committed to the B cell lineage. The clinical presentation of B-ALL Ph′+ is similar to B-ALL, but is more ...

    Bernardo López-Andrade, Francesca Sartori, Antonio Gutiérrez, Lucia García, Vanesa Cunill, María Antonia Durán, Antonia Sampol, Marta Bernués, Julio Iglesias, Rafael Ramos, Josep Lladó, María Sánchez, Juan Carlos Amat and Jordi Martínez-Serra

    Experimental Hematology & Oncology 2016 5:21

    Published on: 29 July 2016

Previous Page Page 1 of 8 Next Page